ArticleLangenbeck's archives of surgery2025
Signet ring cell adenocarcinoma of the ampulla of Vater: does the presence of signet ring cells always suggest a poorer outcome?
Article in Langenbeck's archives of surgery, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
introductionSignet ring cell carcinoma (SRCC) of the ampulla of Vater is a rare histology with very limited data. In the present study, we report the outcomes of this rare pathology after pancreaticoduodenectomy from a single high-volume center. MATERIALS AND
methodsThis is a retrospective study from a prospectively maintained database. All patients who presented to our tertiary cancer hospital with ampullary lesions and underwent pancreaticoduodenectomy between January 2017 and January 2024 were included.
resultsA total of 494 pancreaticoduodenectomies were performed during the study period for ampullary adenocarcinoma. Signet ring cells were present in 35 (7.1%). After propensity matching, the median OS in the signet ring group was not reached versus 55.7 months in the non-signet ring group (p-value-0.853) whereas the median DFS was 33.5 months in the non-signet ring group versus 18.2 months in the signet ring group (p-value-0.729).
conclusionThe presence of signet ring cells on histology after curative pancreaticoduodenectomy for ampullary adenocarcinoma was not associated with poor outcomes. The percentage of signet ring cells also didn't have any effect on survival.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.